Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2021
Randomized Controlled Trial Multicenter StudyBaricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. ⋯ Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.